LCIP
GILD icon

Life Cycle Investment Partners’s Gilead Sciences GILD Stock Holding History

Life Cycle Investment Partners’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$65.9M Buy
521,552
+509,999
+4,414% +$67.2M 0.31% 68
2026
Q1 		$1.61M Hold
11,553
– – 0.01% 122
2025
Q4 		$1.42M Buy
+11,553
New +$1.4M 0.01% 118

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Life Cycle Investment Partners's GILD Position: Q2 2026 in Review

Life Cycle Investment Partners increased its Gilead Sciences (GILD) stake by 4,414% in Q2 2026, buying an estimated $67.2M and bringing the position to 521,552 shares worth $65.9M. The position accounts for 0.31% of the portfolio, ranked #68.

Life Cycle Investment Partners first reported a position in GILD in Q4 2025 and has held it in 3 quarters since. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Life Cycle Investment Partners held 521,552 shares of Gilead Sciences worth $65.9M as of Q2 2026.
  • Life Cycle Investment Partners bought 509,999 Gilead Sciences shares in Q2 2026, an estimated $67.2M.
  • Gilead Sciences made up 0.31% of Life Cycle Investment Partners's portfolio in Q2 2026, its #68 holding.
  • Life Cycle Investment Partners first reported a position in Gilead Sciences in Q4 2025 and has held it in 3 quarters since.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Life Cycle Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.